27164-46-1

• 常用中文名：头孢唑啉钠
• 常用英文名：Cephazolin sodium
• CAS号：27164-46-1
• 分子式：C₁₄H₁₃N₈NaO₄S₃
• 分子量：476.489
• 相关类别： 原料药 抗生素类药物 头孢菌素类药
• 发布时间：2018-02-26 08:00:00
• 更新时间：2024-01-02 17:35:26
• Cefazolin钠是第一代头孢类抗生素, 用于治疗多种细菌感染。

名称

• 中文名: 头孢唑啉钠
• 英文名: cefazolin sodium
• 中文别名: 头孢唑林钠; (6R,7R)-3-[[(5-甲基-1,3,4-噻二唑-2-基)硫]甲基]-7-[(1H-四唑-1-基)乙酰氨基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸钠盐; 唑啉头孢菌素钠
• 英文别名: 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-, monosodium salt, (6R,7R)-; CEFAMEDIN; Biazolina; cephazolin sodium; Cephazolin sodium salt; Azolin; Zolicef; MFCD00056883; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[2-(1H-tetrazol-1-yl)acetyl]amino]-, sodium salt, (6R,7R)- (1:1); Firmacef; SK&F 41558; Lampocef; Sodium (6R,7R)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Cefazolin SodiuM Salt; Cefamezin; Elzogram; Liviclina; Atirin; KEFZOL; Cefazil; Sodium (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Sodium CEZ; (6R,7R)-3-{[(5-méthyl-1,3,4-thiadiazol-2-yl)sulfanyl]méthyl}-8-oxo-7-[(1H-tétrazol-1-ylacétyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate de sodium; Sodium (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Totacef; EINECS 248-278-4; Acef; Cefazina; ancef; Gramaxin; Sodium cefazolin; Cefazolin (sodium)

物化性质

• 熔点: 190 °C
• 分子式: C₁₄H₁₃N₈NaO₄S₃
• 分子量: 476.489
• 精确质量: 476.011963
• PSA: 237.76000
• 外观性状: 淡黄色-白色无气味的,结晶粉末
• 折射率: 20 ° (C=10, H2O)
• 储存条件:

  2-8℃

• 稳定性:

  稳定

• 水溶解性: H2O: 50 mg/mL, clear, colorless
• 计算化学:

  1、 氢键供体数量：2

  2、 氢键受体数量：9

  3、 可旋转化学键数量：7

  4、 互变异构体数量：3

  5、 拓扑分子极性表面积（TPSA）：156

  6、 重原子数：30

  7、 表面电荷：0

  8、 复杂度：740

  9、 同位素原子数量：0

  10、 确定原子立构中心数量：0

  11、 不确定原子立构中心数量：2

  12、 确定化学键立构中心数量：0

  13、 不确定化学键立构中心数量：0

  14、 共价键单元数量：2

• 更多:

  1. 性状：白色或微黄色粉末

  2. 密度（g/mL,25/4℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：未确定

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,5.2kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：未确定

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25ºC）：未确定

  12. 饱和蒸气压（kPa,60ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：难溶于甲醇；乙醇，不溶于丙酮；氯仿

生物活性

• 描述: Cefazolin钠是第一代头孢类抗生素, 用于治疗多种细菌感染。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  研究领域 >> 感染

MSDS

头孢唑啉钠盐 修改号码：5 模块1. 化学品 产品名称： Cefazolin Sodium Salt 修改号码： 5 模块2. 危险性概述 GHS分类 　物理性危害未分类 　健康危害未分类 　环境危害未分类 GHS标签元素 　图标或危害标志无 　信号词无信号词 　危险描述无 　防范说明无 模块3. 成分/组成信息 单一物质/混和物单一物质 化学名(中文名)：头孢唑啉钠盐 百分比： >97.0%(LC)(T) CAS编码： 27164-46-1 分子式： C14H13N8NaO4S3 模块4. 急救措施 吸入： 将受害者移到新鲜空气处，保持呼吸通畅，休息。若感不适请求医/就诊。 皮肤接触： 立即去除/脱掉所有被污染的衣物。用水清洗皮肤/淋浴。 若皮肤刺激或发生皮疹：求医/就诊。 眼睛接触：用水小心清洗几分钟。如果方便，易操作，摘除隐形眼镜。继续清洗。 如果眼睛刺激：求医/就诊。 食入： 若感不适，求医/就诊。漱口。 紧急救助者的防护：救援者需要穿戴个人防护用品，比如橡胶手套和气密性护目镜。 模块5. 消防措施 合适的灭火剂：干粉，泡沫，雾状水，二氧化碳 特殊危险性：小心，燃烧或高温下可能分解产生毒烟。 头孢唑啉钠盐 修改号码：5 模块5. 消防措施 特定方法：从上风处灭火，根据周围环境选择合适的灭火方法。 非相关人员应该撤离至安全地方。 周围一旦着火：如果安全，移去可移动容器。 消防员的特殊防护用具：灭火时，一定要穿戴个人防护用品。 模块6. 泄漏应急处理 个人防护措施，防护用具， 使用个人防护用品。远离溢出物/泄露处并处在上风处。 紧急措施：泄露区应该用安全带等圈起来，控制非相关人员进入。 环保措施：防止进入下水道。 控制和清洗的方法和材料：清扫收集粉尘，封入密闭容器。注意切勿分散。附着物或收集物应该立即根据合适的 法律法规处置。 模块7. 操作处置与储存 处理 技术措施：在通风良好处进行处理。穿戴合适的防护用具。防止粉尘扩散。处理后彻底清洗双手 和脸。 注意事项：如果粉尘或浮质产生，使用局部排气。 操作处置注意事项：避免接触皮肤、眼睛和衣物。 贮存 储存条件：保持容器密闭。冷藏储存。 远离不相容的材料比如氧化剂存放。 热敏 包装材料：依据法律。 模块8. 接触控制和个体防护 工程控制：尽可能安装封闭体系或局部排风系统，操作人员切勿直接接触。同时安装淋浴器和洗 眼器。 个人防护用品 　呼吸系统防护：防尘面具。依据当地和政府法规。 　手部防护：防护手套。 　眼睛防护：安全防护镜。如果情况需要，佩戴面具。 　皮肤和身体防护：防护服。如果情况需要，穿戴防护靴。 模块9. 理化特性 固体 外形（20°C）： 外观： 晶体-粉末 颜色： 白色-浅黄色 气味：无味 pH:无数据资料 熔点： 190°C 沸点/沸程无资料 闪点：无资料 爆炸特性 　爆炸下限：无资料 　爆炸上限：无资料 密度：无资料 溶解度： [水]易溶于 [其他溶剂] 头孢唑啉钠盐 修改号码：5 模块9. 理化特性 微溶于： 甲醇, 乙醇 不溶于： 苯, 丙酮, 氯仿 模块10. 稳定性和反应性 化学稳定性：一般情况下稳定。 危险反应的可能性：未报道特殊反应性。 须避免接触的物质氧化剂 危险的分解产物: 一氧化碳, 二氧化碳, 氮氧化物 (NOx), 硫氧化物 模块11. 毒理学信息 急性毒性： orl-rat LD50:>11 g/kg ipr-rat LD50:7400 mg/kg ivn-rat LD50:2760 mg/kg scu-rat LD50:10 g/kg 对皮肤腐蚀或刺激：无资料 对眼睛严重损害或刺激：无资料 生殖细胞变异原性：无资料 致癌性： IARC =无资料 NTP =无资料 生殖毒性：无资料 RTECS 号码: XI0390000 模块12. 生态学信息 生态毒性： 鱼类：无资料 甲壳类：无资料 藻类：无资料 残留性 / 降解性：无资料 潜在生物累积 （BCF):无资料 土壤中移动性 　log水分配系数：无资料 　土壤吸收系数 （Koc）：无资料 　亨利定律无资料 constant(PaM3/mol): 模块13. 废弃处置 如果可能，回收处理。请咨询当地管理部门。建议在可燃溶剂中溶解混合，在装有后燃和洗涤装置的化学焚烧炉中 焚烧。废弃处置时请遵守国家、地区和当地的所有法规。 模块14. 运输信息 联合国分类：与联合国分类标准不一致 UN编号：未列明 模块15. 法规信息 《危险化学品安全管理条例》（2002年1月26日国务院发布，2011年2月16日修订）: 针对危险化学品的安全使用、 生产、储存、运输、装卸等方面均作了相应的规定。 头孢唑啉钠盐 修改号码：5 模块16 - 其他信息 N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : XI0390000 CHEMICAL NAME : 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl) thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)amino )-, (6R-trans)-, sodium salt CAS REGISTRY NUMBER : 27164-46-1 LAST UPDATED : 199706 DATA ITEMS CITED : 28 MOLECULAR FORMULA : C14-H13-N8-O4-S3.Na MOLECULAR WEIGHT : 476.52 WISWESSER LINE NOTATION : T46 ANV ES GUTJ HVO CMV1- AT5NNNNJ& G1S- CT5NN DSJ E1 &-NA- HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - woman DOSE/DURATION : 660 mg/kg/11D-I TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold REFERENCE : NPRNAY Nephron. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1964- Volume(issue)/page/year: 45,72,1987 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Human DOSE/DURATION : 14 mg/kg/D TOXIC EFFECTS : Gastrointestinal - changes in structure or function of salivary glands Gastrointestinal - nausea or vomiting Skin and Appendages - dermatitis, allergic (after systemic exposure) REFERENCE : JMGZAI Japan Medical Gazette. (Tokyo, Japan) V.1-18(?), 1964-81. Discontinued. Volume(issue)/page/year: 8(8),10,1971 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >11 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 7400 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,404,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 10 gm/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Gastrointestinal - hypermotility, diarrhea REFERENCE : JMGZAI Japan Medical Gazette. (Tokyo, Japan) V.1-18(?), 1964-81. Discontinued. Volume(issue)/page/year: 8(8),10,1971 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2760 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 35(Suppl 1),207,1987 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >11 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 6200 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,404,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 7600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : JIDIAQ Journal of Infectious Diseases. (Univ. of Chicago Press, Journals Div., POB 37005, Chicago, IL 60637) V.1- 1904- Volume(issue)/page/year: 128,S379,1973 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3900 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : JIDIAQ Journal of Infectious Diseases. (Univ. of Chicago Press, Journals Div., POB 37005, Chicago, IL 60637) V.1- 1904- Volume(issue)/page/year: 128,S379,1973 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 4 gm/kg TOXIC EFFECTS : Gastrointestinal - changes in structure or function of salivary glands Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 2200 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 29,424,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : >6 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 2500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 29,424,1979 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 112 gm/kg/28D-I TOXIC EFFECTS : Blood - normocytic anemia Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - changes in prostate weight REFERENCE : JZKEDZ Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. (Jikken Dobutsu Chuo Kenkyusho, 1433 Nogawa, Takatsu-ku, Kawasaki 211, Japan) V.1- 1975- Volume(issue)/page/year: 2,1,1976 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 91 gm/kg/13W-I TOXIC EFFECTS : Endocrine - changes in spleen weight Blood - changes in spleen Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 21 gm/kg/21D-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - other changes in urine composition Nutritional and Gross Metabolic - changes in chlorine REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 4),162,1992 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 42875 mg/kg/5W-I TOXIC EFFECTS : Gastrointestinal - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 18,1793,1984 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 91 gm/kg/13W-I TOXIC EFFECTS : Blood - normocytic anemia Blood - changes in spleen Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 45500 mg/kg/26W-I TOXIC EFFECTS : Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 72 gm/kg/13W-I TOXIC EFFECTS : Liver - changes in liver weight Blood - normocytic anemia Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 35(Suppl 1),251,1987 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 7500 mg/kg/30D-I TOXIC EFFECTS : Gastrointestinal - nausea or vomiting Liver - fatty liver degeneration Kidney, Ureter, Bladder - other changes REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 18,528,1970 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 2800 mg/kg/7D-I TOXIC EFFECTS : Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases Related to Chronic Data - death REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 27(Suppl 5),701,1979 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 5500 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 7),1119,1980 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 5500 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 7),1119,1980 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 21 gm/kg SEX/DURATION : female 17-22 day(s) after conception lactating female 20 day(s) post-birth TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 35(Suppl 1),404,1987 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 21 gm/kg SEX/DURATION : female 17-22 day(s) after conception lactating female 20 day(s) post-birth TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 35(Suppl 1),404,1987 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3195 No. of Facilities: 675 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 27888 (estimated) No. of Female Employees: 22194 (estimated)

安全

• 符号: GHS08
• 信号词: Danger
• 危害声明: H317-H334
• 警示性声明: P261-P280-P342 + P311
• 个人防护装备: dust mask type N95 (US);Eyeshields;Faceshields;Gloves
• 危害码 (欧洲): Xn:Harmful
• 风险声明 (欧洲): R42/43
• 安全声明 (欧洲): S22-S36/37
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 2
• RTECS号: XI0390000
• 海关编码: 2941905300

上下游产品

上游产品  0
下游产品  1
25953-19-9

海关

海关编码	2941905300